RR-A3 (LY3437943) is a novel triple-receptor agonist that simultaneously activates GLP-1, GIP, and Glucagon receptors—a first-in-class approach to metabolic research. - Composition: 39-amino acid peptide - Conjugation: C20 fatty diacid moiety for albumin binding - Half-life: Approximately 6 days - Administration: Once-weekly subcutaneous injection | Receptor | Primary Effects | |----------|-----------------| | GLP-1 | Reduces appetite, slows gastric emptying, enhances insulin secretion | | GIP | Stimulates insulin release, reduces appetite, impacts fat metabolism | | Glucagon | Increases energy expenditure, promotes lipolysis, enhances thermogenesis | Compared to natural hormones: - 0.3× potency at glucagon receptors - 0.4× potency at GLP-1 receptors - 8.9× more potent at GIP receptors Phase 2 research demonstrated: - Significant reductions in body weight at 48 weeks - Improvements in metabolic markers - Enhanced glycemic control indicators - Weight effects not yet plateaue
RR-A3: Triple Agonist Research Guide
Exploring RR-A3, the novel triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors.